Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates.

Gilchuk P, Mire CE, Geisbert JB, Agans KN, Deer DJ, Cross RW, Slaughter JC, Flyak AI, Mani J, Pauly MH, Velasco J, Whaley KJ, Zeitlin L, Geisbert TW, Crowe JE Jr.

J Infect Dis. 2018 Jul 5. doi: 10.1093/infdis/jiy295. [Epub ahead of print]

PMID:
29982718
2.

Marburg and Ravn Viruses Fail to Cause Disease in the Domestic Ferret (Mustela putorius furo).

Cross RW, Mire CE, Agans KN, Borisevich V, Fenton KA, Geisbert TW.

J Infect Dis. 2018 Jun 28. doi: 10.1093/infdis/jiy268. [Epub ahead of print]

PMID:
29955887
3.

Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms.

Warfield KL, Howell KA, Vu H, Geisbert J, Wong G, Shulenin S, Sproule S, Holtsberg FW, Leung DW, Amarasinghe GK, Swenson DL, Bavari S, Kobinger GP, Geisbert TW, Aman MJ.

J Infect Dis. 2018 Jun 25. doi: 10.1093/infdis/jiy316. [Epub ahead of print]

PMID:
29939318
4.

Postexposure Efficacy of Recombinant Vesicular Stomatitis Virus Vectors Against High and Low Doses of Marburg Virus Variant Angola in Nonhuman Primates.

Woolsey C, Geisbert JB, Matassov D, Agans KN, Borisevich V, Cross RW, Deer DJ, Fenton KA, Eldridge JH, Mire CE, Geisbert TW.

J Infect Dis. 2018 Jun 25. doi: 10.1093/infdis/jiy293. [Epub ahead of print]

PMID:
29939296
5.

Post-exposure treatments for Ebola and Marburg virus infections.

Cross RW, Mire CE, Feldmann H, Geisbert TW.

Nat Rev Drug Discov. 2018 May 4. doi: 10.1038/nrd.2018.73. [Epub ahead of print]

PMID:
29725132
6.

Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Apr 24;13(4):e0196546. doi: 10.1371/journal.pone.0196546. eCollection 2018.

7.

Field validation of recombinant antigen immunoassays for diagnosis of Lassa fever.

Boisen ML, Hartnett JN, Shaffer JG, Goba A, Momoh M, Sandi JD, Fullah M, Nelson DKS, Bush DJ, Rowland MM, Heinrich ML, Koval AP, Cross RW, Barnes KG, Lachenauer AE, Lin AE, Nekoui M, Kotliar D, Winnicki SM, Siddle KJ, Gbakie M, Fonnie M, Koroma VJ, Kanneh L, Kulakosky PC, Hastie KM, Wilson RB, Andersen KG, Folarin OO, Happi CT, Sabeti PC, Geisbert TW, Saphire EO, Khan SH, Grant DS, Schieffelin JS, Branco LM, Garry RF.

Sci Rep. 2018 Apr 12;8(1):5939. doi: 10.1038/s41598-018-24246-w.

8.

Predicting outcome and improving treatment for Lassa fever.

Geisbert TW.

Lancet Infect Dis. 2018 Jun;18(6):594-595. doi: 10.1016/S1473-3099(18)30116-6. Epub 2018 Mar 6. No abstract available.

PMID:
29523495
9.

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.

Callendret B, Vellinga J, Wunderlich K, Rodriguez A, Steigerwald R, Dirmeier U, Cheminay C, Volkmann A, Brasel T, Carrion R, Giavedoni LD, Patterson JL, Mire CE, Geisbert TW, Hooper JW, Weijtens M, Hartkoorn-Pasma J, Custers J, Grazia Pau M, Schuitemaker H, Zahn R.

PLoS One. 2018 Feb 20;13(2):e0192312. doi: 10.1371/journal.pone.0192312. eCollection 2018. Erratum in: PLoS One. 2018 Apr 24;13(4):e0196546.

10.

Post-exposure treatments for Ebola and Marburg virus infections.

Cross RW, Mire CE, Feldmann H, Geisbert TW.

Nat Rev Drug Discov. 2018 Jun;17(6):413-434. doi: 10.1038/nrd.2017.251. Epub 2018 Jan 29. Review. Erratum in: Nat Rev Drug Discov. 2018 May 04;:.

PMID:
29375139
11.

Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.

Matassov D, Mire CE, Latham T, Geisbert JB, Xu R, Ota-Setlik A, Agans KN, Kobs DJ, Wendling MQS, Burnaugh A, Rudge TL Jr, Sabourin CL, Egan MA, Clarke DK, Geisbert TW, Eldridge JH.

J Virol. 2017 Nov 15. pii: JVI.01190-17. doi: 10.1128/JVI.01190-17. [Epub ahead of print]

12.

Transcriptome Analysis of Circulating Immune Cell Subsets Highlight the Role of Monocytes in Zaire Ebola Virus Makona Pathogenesis.

Menicucci AR, Versteeg K, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jankeel A, Geisbert TW, Messaoudi I.

Front Immunol. 2017 Oct 26;8:1372. doi: 10.3389/fimmu.2017.01372. eCollection 2017.

13.

siRNA rescues nonhuman primates from advanced Marburg and Ravn virus disease.

Thi EP, Mire CE, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Cross RW, Kondratowicz AS, Fenton KA, MacLachlan I, Geisbert TW.

J Clin Invest. 2017 Dec 1;127(12):4437-4448. doi: 10.1172/JCI96185. Epub 2017 Nov 6.

14.

Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, Heinrich ML, Rowland MM, Goba A, Momoh M, Boisen ML, Grant DS, Fullah M, Khan SH, Fenton KA, Robinson JE, Branco LM, Garry RF, Geisbert TW.

Nat Med. 2017 Oct;23(10):1146-1149. doi: 10.1038/nm.4396. Epub 2017 Sep 4.

15.

Infection with the Makona variant results in a delayed and distinct host immune response compared to previous Ebola virus variants.

Versteeg K, Menicucci AR, Woolsey C, Mire CE, Geisbert JB, Cross RW, Agans KN, Jeske D, Messaoudi I, Geisbert TW.

Sci Rep. 2017 Aug 29;7(1):9730. doi: 10.1038/s41598-017-09963-y.

16.

Neutralizing the Threat: Pan-Ebolavirus Antibodies Close the Loop.

Mire CE, Geisbert TW.

Trends Mol Med. 2017 Aug;23(8):669-671. doi: 10.1016/j.molmed.2017.06.008. Epub 2017 Jul 8.

17.

Enhanced light microscopy visualization of virus particles from Zika virus to filamentous ebolaviruses.

Daaboul GG, Freedman DS, Scherr SM, Carter E, Rosca A, Bernstein D, Mire CE, Agans KN, Hoenen T, Geisbert TW, Ünlü MS, Connor JH.

PLoS One. 2017 Jun 26;12(6):e0179728. doi: 10.1371/journal.pone.0179728. eCollection 2017.

18.

Evaluation of Medical Countermeasures Against Ebolaviruses in Nonhuman Primate Models.

Mire CE, Geisbert TW.

Methods Mol Biol. 2017;1628:293-307. doi: 10.1007/978-1-4939-7116-9_24.

PMID:
28573630
19.

Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody.

Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE Jr, Zeitlin L, Geisbert TW.

Sci Transl Med. 2017 Apr 5;9(384). pii: eaai8711. doi: 10.1126/scitranslmed.aai8711.

20.

Disposable cartridge platform for rapid detection of viral hemorrhagic fever viruses.

Scherr SM, Freedman DS, Agans KN, Rosca A, Carter E, Kuroda M, Fawcett HE, Mire CE, Geisbert TW, Ünlü MS, Connor JH.

Lab Chip. 2017 Feb 28;17(5):917-925. doi: 10.1039/c6lc01528j.

PMID:
28194457
21.

First Ebola virus vaccine to protect human beings?

Geisbert TW.

Lancet. 2017 Feb 4;389(10068):479-480. doi: 10.1016/S0140-6736(16)32618-6. Epub 2016 Dec 23. No abstract available.

22.

Persistence of Ebola virus RNA in seminal fluid.

Geisbert TW.

Lancet Glob Health. 2017 Jan;5(1):e12-e13. doi: 10.1016/S2214-109X(16)30336-9. No abstract available.

23.

Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.

Warfield KL, Warren TK, Qiu X, Wells J, Mire CE, Geisbert JB, Stuthman KS, Garza NL, Van Tongeren SA, Shurtleff AC, Agans KN, Wong G, Callahan MV, Geisbert TW, Klose B, Ramstedt U, Treston AM.

Antiviral Res. 2017 Feb;138:22-31. doi: 10.1016/j.antiviral.2016.11.019. Epub 2016 Nov 28.

PMID:
27908828
24.

Rescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNA.

Thi EP, Lee AC, Geisbert JB, Ursic-Bedoya R, Agans KN, Robbins M, Deer DJ, Fenton KA, Kondratowicz AS, MacLachlan I, Geisbert TW, Mire CE.

Nat Microbiol. 2016 Aug 22;1(10):16142. doi: 10.1038/nmicrobiol.2016.142.

25.

Molecular Diagnostic Field Test for Point-of-Care Detection of Ebola Virus Directly From Blood.

Benzine JW, Brown KM, Agans KN, Godiska R, Mire CE, Gowda K, Converse B, Geisbert TW, Mead DA, Chander Y.

J Infect Dis. 2016 Oct 15;214(suppl 3):S234-S242. Epub 2016 Sep 16.

26.

Analytical Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Cross RW, Boisen ML, Millett MM, Nelson DS, Oottamasathien D, Hartnett JN, Jones AB, Goba A, Momoh M, Fullah M, Bornholdt ZA, Fusco ML, Abelson DM, Oda S, Brown BL, Pham H, Rowland MM, Agans KN, Geisbert JB, Heinrich ML, Kulakosky PC, Shaffer JG, Schieffelin JS, Kargbo B, Gbetuwa M, Gevao SM, Wilson RB, Saphire EO, Pitts KR, Khan SH, Grant DS, Geisbert TW, Branco LM, Garry RF.

J Infect Dis. 2016 Oct 15;214(suppl 3):S210-S217. Epub 2016 Aug 31.

27.

Passive Immunotherapy: Assessment of Convalescent Serum Against Ebola Virus Makona Infection in Nonhuman Primates.

Mire CE, Geisbert JB, Agans KN, Thi EP, Lee AC, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S367-S374. Epub 2016 Aug 28.

28.

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.

Cross RW, Mire CE, Branco LM, Geisbert JB, Rowland MM, Heinrich ML, Goba A, Momoh M, Grant DS, Fullah M, Khan SH, Robinson JE, Geisbert TW, Garry RF.

Antiviral Res. 2016 Sep;133:218-222. doi: 10.1016/j.antiviral.2016.08.012. Epub 2016 Aug 13.

29.

Field Validation of the ReEBOV Antigen Rapid Test for Point-of-Care Diagnosis of Ebola Virus Infection.

Boisen ML, Cross RW, Hartnett JN, Goba A, Momoh M, Fullah M, Gbakie M, Safa S, Fonnie M, Baimba F, Koroma VJ, Geisbert JB, McCormick S, Nelson DK, Millett MM, Oottamasathien D, Jones AB, Pham H, Brown BL, Shaffer JG, Schieffelin JS, Kargbo B, Gbetuwa M, Gevao SM, Wilson RB, Pitts KR, Geisbert TW, Branco LM, Khan SH, Grant DS, Garry RF.

J Infect Dis. 2016 Oct 15;214(suppl 3):S203-S209. Epub 2016 Aug 11.

30.

Pathogenic Differences between Nipah Virus Bangladesh and Malaysia Strains in Primates: Implications for Antibody Therapy.

Mire CE, Satterfield BA, Geisbert JB, Agans KN, Borisevich V, Yan L, Chan YP, Cross RW, Fenton KA, Broder CC, Geisbert TW.

Sci Rep. 2016 Aug 3;6:30916. doi: 10.1038/srep30916.

31.

An Outbreak of Ebola Virus Disease in the Lassa Fever Zone.

Goba A, Khan SH, Fonnie M, Fullah M, Moigboi A, Kovoma A, Sinnah V, Yoko N, Rogers H, Safai S, Momoh M, Koroma V, Kamara FK, Konowu E, Yillah M, French I, Mustapha I, Kanneh F, Foday M, McCarthy H, Kallon T, Kallon M, Naiebu J, Sellu J, Jalloh AA, Gbakie M, Kanneh L, Massaly JL, Kargbo D, Kargbo B, Vandi M, Gbetuwa M, Gevao SM, Sandi JD, Jalloh SC, Grant DS, Blyden SO, Crozier I, Schieffelin JS, McLellan SL, Jacob ST, Boisen ML, Hartnett JN, Cross RW, Branco LM, Andersen KG, Yozwiak NL, Gire SK, Tariyal R, Park DJ, Haislip AM, Bishop CM, Melnik LI, Gallaher WR, Wimley WC, He J, Shaffer JG, Sullivan BM, Grillo S, Oman S, Garry CE, Edwards DR, McCormick SJ, Elliott DH, Rouelle JA, Kannadka CB, Reyna AA, Bradley BT, Yu H, Yenni RE, Hastie KM, Geisbert JB, Kulakosky PC, Wilson RB, Oldstone MB, Pitts KR, Henderson LA, Robinson JE, Geisbert TW, Saphire EO, Happi CT, Asogun DA, Sabeti PC, Garry RF; Viral Hemorrhagic Fever Consortium.

J Infect Dis. 2016 Oct 15;214(suppl 3):S110-S121. Epub 2016 Jul 11.

32.

The Domestic Ferret (Mustela putorius furo) as a Lethal Infection Model for 3 Species of Ebolavirus.

Cross RW, Mire CE, Borisevich V, Geisbert JB, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Aug 15;214(4):565-9. doi: 10.1093/infdis/jiw209. Epub 2016 May 24.

33.

Isolation and Characterization of a Novel Gammaherpesvirus from a Microbat Cell Line.

Shabman RS, Shrivastava S, Tsibane T, Attie O, Jayaprakash A, Mire CE, Dilley KE, Puri V, Stockwell TB, Geisbert TW, Sachidanandam R, Basler CF.

mSphere. 2016 Feb 17;1(1). pii: e00070-15. doi: 10.1128/mSphere.00070-15. eCollection 2016 Jan-Feb.

34.

Oral and Conjunctival Exposure of Nonhuman Primates to Low Doses of Ebola Makona Virus.

Mire CE, Geisbert JB, Agans KN, Deer DJ, Fenton KA, Geisbert TW.

J Infect Dis. 2016 Oct 15;214(suppl 3):S263-S267. Epub 2016 Jun 9.

35.

Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Robinson JE, Hastie KM, Cross RW, Yenni RE, Elliott DH, Rouelle JA, Kannadka CB, Smira AA, Garry CE, Bradley BT, Yu H, Shaffer JG, Boisen ML, Hartnett JN, Zandonatti MA, Rowland MM, Heinrich ML, Martínez-Sobrido L, Cheng B, de la Torre JC, Andersen KG, Goba A, Momoh M, Fullah M, Gbakie M, Kanneh L, Koroma VJ, Fonnie R, Jalloh SC, Kargbo B, Vandi MA, Gbetuwa M, Ikponmwosa O, Asogun DA, Okokhere PO, Follarin OA, Schieffelin JS, Pitts KR, Geisbert JB, Kulakoski PC, Wilson RB, Happi CT, Sabeti PC, Gevao SM, Khan SH, Grant DS, Geisbert TW, Saphire EO, Branco LM, Garry RF.

Nat Commun. 2016 May 10;7:11544. doi: 10.1038/ncomms11544.

36.

Nipah Virus C and W Proteins Contribute to Respiratory Disease in Ferrets.

Satterfield BA, Cross RW, Fenton KA, Borisevich V, Agans KN, Deer DJ, Graber J, Basler CF, Geisbert TW, Mire CE.

J Virol. 2016 Jun 24;90(14):6326-6343. doi: 10.1128/JVI.00215-16. Print 2016 Jul 15.

37.

Ebola virus vaccines - reality or fiction?

Mire CE, Geisbert TW, Feldmann H, Marzi A.

Expert Rev Vaccines. 2016 Nov;15(11):1421-1430. Epub 2016 May 9. Review.

38.

Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses.

Whitt MA, Geisbert TW, Mire CE.

Methods Mol Biol. 2016;1403:295-311. doi: 10.1007/978-1-4939-3387-7_16.

PMID:
27076138
39.

Monoclonal antibody therapy for Junin virus infection.

Zeitlin L, Geisbert JB, Deer DJ, Fenton KA, Bohorov O, Bohorova N, Goodman C, Kim D, Hiatt A, Pauly MH, Velasco J, Whaley KJ, Altmann F, Gruber C, Steinkellner H, Honko AN, Kuehne AI, Aman MJ, Sahandi S, Enterlein S, Zhan X, Enria D, Geisbert TW.

Proc Natl Acad Sci U S A. 2016 Apr 19;113(16):4458-63. doi: 10.1073/pnas.1600996113. Epub 2016 Apr 4.

40.

Differential Regulation of Interferon Responses by Ebola and Marburg Virus VP35 Proteins.

Edwards MR, Liu G, Mire CE, Sureshchandra S, Luthra P, Yen B, Shabman RS, Leung DW, Messaoudi I, Geisbert TW, Amarasinghe GK, Basler CF.

Cell Rep. 2016 Feb 23;14(7):1632-1640. doi: 10.1016/j.celrep.2016.01.049. Epub 2016 Feb 11.

41.

The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.

Pécheur EI, Borisevich V, Halfmann P, Morrey JD, Smee DF, Prichard M, Mire CE, Kawaoka Y, Geisbert TW, Polyak SJ.

J Virol. 2016 Jan 6;90(6):3086-92. doi: 10.1128/JVI.02077-15.

42.

Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway.

Pattabhi S, Wilkins CR, Dong R, Knoll ML, Posakony J, Kaiser S, Mire CE, Wang ML, Ireton RC, Geisbert TW, Bedard KM, Iadonato SP, Loo YM, Gale M Jr.

J Virol. 2015 Dec 16;90(5):2372-87. doi: 10.1128/JVI.02202-15.

43.

The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.

Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, Geisbert J, Saturday G, Komeno T, Geisbert TW, Feldmann H, Gowen BB.

Sci Rep. 2015 Oct 12;5:14775. doi: 10.1038/srep14775.

44.

Development of Prototype Filovirus Recombinant Antigen Immunoassays.

Boisen ML, Oottamasathien D, Jones AB, Millett MM, Nelson DS, Bornholdt ZA, Fusco ML, Abelson DM, Oda S, Hartnett JN, Rowland MM, Heinrich ML, Akdag M, Goba A, Momoh M, Fullah M, Baimba F, Gbakie M, Safa S, Fonnie R, Kanneh L, Cross RW, Geisbert JB, Geisbert TW, Kulakosky PC, Grant DS, Shaffer JG, Schieffelin JS, Wilson RB, Saphire EO, Branco LM, Garry RF, Khan SH, Pitts KR; Viral Hemorrhagic Fever Consortium.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S359-67. doi: 10.1093/infdis/jiv353. Epub 2015 Jul 30.

45.

Aerosolized Ebola vaccine protects primates and elicits lung-resident T cell responses.

Meyer M, Garron T, Lubaki NM, Mire CE, Fenton KA, Klages C, Olinger GG, Geisbert TW, Collins PL, Bukreyev A.

J Clin Invest. 2015 Aug 3;125(8):3241-55. doi: 10.1172/JCI81532. Epub 2015 Jul 13.

46.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.

Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.

47.

The immunomodulating V and W proteins of Nipah virus determine disease course.

Satterfield BA, Cross RW, Fenton KA, Agans KN, Basler CF, Geisbert TW, Mire CE.

Nat Commun. 2015 Jun 24;6:7483. doi: 10.1038/ncomms8483.

48.

Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model.

Cross RW, Fenton KA, Geisbert JB, Ebihara H, Mire CE, Geisbert TW.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S258-70. doi: 10.1093/infdis/jiv182. Epub 2015 Jun 19.

49.

Considerations in the Use of Nonhuman Primate Models of Ebola Virus and Marburg Virus Infection.

Geisbert TW, Strong JE, Feldmann H.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S91-7. doi: 10.1093/infdis/jiv284. Epub 2015 Jun 10.

50.

Modeling the Disease Course of Zaire ebolavirus Infection in the Outbred Guinea Pig.

Cross RW, Fenton KA, Geisbert JB, Mire CE, Geisbert TW.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S305-15. doi: 10.1093/infdis/jiv237. Epub 2015 Jun 2.

PMID:
26038397

Supplemental Content

Loading ...
Support Center